All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for TAKEDA PHARMACEUTICALS AMERICA, INC. · pharmaceutical company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Illinois · House · Senate · $50,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 2

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 891
Bipartisan Health Care Act

Lobbying activity 6

Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; orphan drug tax credit; Inflation Reduction Act of 2022 (P.L.117-169) implementation; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21).

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Health Issues

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Budget/Appropriations

H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.